

the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States. Additional information on all bank holding companies may be obtained from the National Information Center website at [www.ffiec.gov/nic/](http://www.ffiec.gov/nic/).

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than March 26, 2010.

**A. Federal Reserve Bank of Kansas City** (Dennis Denney, Assistant Vice President) 1 Memorial Drive, Kansas City, Missouri 64198-0001:

1. *Platte Valley Bancorp, Inc.*, to become a bank holding company by acquiring 100 percent of the voting shares of Platte Valley Bank, both of North Bend, Nebraska.

**B. Federal Reserve Bank of San Francisco** (Kenneth Binning, Vice President, Applications and Enforcement) 101 Market Street, San Francisco, California 94105-1579:

1. *Franklin Resources, Inc.*, San Mateo, California; to retain 9.53 percent of the voting shares of West Coast Bancorp, and thereby indirectly retain voting shares of West Coast Bank, both of Lake Oswego, Oregon.

Board of Governors of the Federal Reserve System, February 25, 2010.

**Robert deV. Frierson,**

*Deputy Secretary of the Board.*

[FR Doc. 2010-4227 Filed 3-1-10; 8:45 am]

**BILLING CODE 6210-01-S**

## FEDERAL RESERVE SYSTEM

### Notice of Proposals to Engage in Permissible Nonbanking Activities or to Acquire Companies that are Engaged in Permissible Nonbanking Activities

The companies listed in this notice have given notice under section 4 of the Bank Holding Company Act (12 U.S.C. 1843) (BHC Act) and Regulation Y (12 CFR Part 225) to engage *de novo*, or to acquire or control voting securities or assets of a company, including the companies listed below, that engages either directly or through a subsidiary or other company, in a nonbanking activity that is listed in § 225.28 of Regulation Y (12 CFR 225.28) or that the Board has determined by Order to be closely related to banking and permissible for bank holding companies. Unless otherwise noted, these activities will be conducted throughout the United States.

Each notice is available for inspection at the Federal Reserve Bank indicated. The notice also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether the proposal complies with the standards of section 4 of the BHC Act. Additional information on all bank holding companies may be obtained from the National Information Center website at [www.ffiec.gov/nic/](http://www.ffiec.gov/nic/).

Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than March 17, 2010.

**A. Federal Reserve Bank of Chicago** (Colette A. Fried, Assistant Vice President) 230 South LaSalle Street, Chicago, Illinois 60690-1414:

1. *Northwest Financial Corp.*, Arnolds Park, Iowa; to engage *de novo* through its subsidiary, Northwest Wealth Management, LLC, Arnolds Park, Iowa,

in investment advisory and transactional activities, pursuant to sections 225.28(b)(6)(i); (b)(6)(ii); (b)(6)(v); (b)(7)(i); (b)(7)(ii) and (b)(9)(ii), all of Regulation Y.

Board of Governors of the Federal Reserve System, February 25, 2010.

**Robert deV. Frierson,**

*Deputy Secretary of the Board.*

[FR Doc. 2010-4226 Filed 3-1-10; 8:45 am]

**BILLING CODE 6210-01-S**

## FEDERAL MARITIME COMMISSION

### Notice of Hearing Schedule; Passenger Vessel Financial Responsibility

The Commission has established the following allotment of time and order of presentation for the hearing concerning the Commission's Passenger Vessel Financial Responsibility Program. The hearing will convene at 10 a.m., March 3, 2010, in the Commission's Main Hearing Room, Room 100, 800 North Capitol Street, NW., Washington, DC 20573. In the event that additional time is needed to hear all participants and allow presenters to field questions from the Commission, an afternoon session will be convened.

The due date for submitting the original and 15 copies of participant's prepared hearing statement is Friday, February 26, 2010. All written submissions, except for confidential business information, will be available for public inspection.

Company	Participant(s)	Time allotment (in minutes)
American Cruise Lines Inc. ....	Charles A. Robertson, Chairman & Chief Executive Officer .....	15
Carnival Corporation & PLC .....	David Bernstein, Senior Vice President & Chief Financial Officer.	15
Crystal Cruises, Inc. ....	Ann G. Miller, Law Offices of Ann G. Miller .....	15
Cruise Lines International Association .....	Terry L. Dale, President and CEO, J. Michael Cavanaugh, Holland & Knight LLP.	15
Passenger Vessel Association .....	Ed Welch, Legislative Director .....	15

Karen V. Gregory,  
Secretary.

[FR Doc. 2010-4202 Filed 3-1-10; 8:45 am]

BILLING CODE 6730-01-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA-2010-N-0001]

### Advisory Committee Information Hotline

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing that we have revised the Advisory

Committee Information Hotline (the hotline). The hotline provides the public with access to the most current information available on FDA advisory committee meetings. This notice supersedes all previously published announcements of FDA's Advisory Committee Information Hotline.

**FOR FURTHER INFORMATION CONTACT:** Michael F. Ortwerth, Director, Advisory Committee Oversight and Management Staff (HF-4), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-1220.

**SUPPLEMENTARY INFORMATION:** The Advisory Committee Information Hotline can be accessed by dialing 1-800-741-8138 or 301-443-0572. The advisory committee meeting information and information updates can also be accessed via FDA's Advisory

Committee Internet site at <http://www.fda.gov/AdvisoryCommittees/default.htm>.

Each advisory committee is assigned a 10-digit number. This 10-digit number will appear in each individual notice of meeting. The public can obtain information about a particular advisory committee meeting by using the committee's 10-digit number. Information on the hotline is preliminary and may change before a meeting is actually held. The hotline will be updated when such changes are made. The following is a list of each advisory committee's 10-digit number to be used when accessing the hotline. The list has been updated to add the newly established advisory committee in the Center for Tobacco called the Tobacco Products Scientific Advisory Committee.

Advisory Committee	10-Digit Access Number
OFFICE OF THE COMMISSIONER	
Pediatric Advisory Committee	8732310001
Risk Communication Advisory Committee	8732112560
Science Board to the FDA	3014512603
CENTER FOR BIOLOGICS EVALUATION AND RESEARCH	
Allergenic Products Advisory Committee	3014512388
Blood Products Advisory Committee	3014519516
Cellular, Tissue & Gene Therapies Advisory Committee	3014512389
Transmissible Spongiform Encephalopathies Advisory Committee	3014512392
Vaccines and Related Biological Products Advisory Committee	3014512391
CENTER FOR DRUG EVALUATION AND RESEARCH	
Anesthetic and Life Support Drugs Advisory Committee	3014512529
Anti-Infective Drugs Advisory Committee	3014512530
Antiviral Drugs Advisory Committee	3014512531
Arthritis Advisory Committee	3014512532
Cardiovascular and Renal Drugs Advisory Committee	3014512533
Dermatologic and Ophthalmic Drugs Advisory Committee	3014512534
Drug Safety and Risk Management Advisory Committee	3014512535
Endocrinologic and Metabolic Drugs Advisory Committee	3014512536
Gastrointestinal Drugs Advisory Committee	3014512538
Nonprescription Drugs Advisory Committee	3014512541
Oncologic Drugs Advisory Committee	3014512542
Peripheral and Central Nervous System Drugs Advisory Committee	3014512543
Pharmaceutical Science & Clinical Pharmacology, Advisory Committee for (formerly Advisory Committee for Pharmaceutical Science)	3014512539